A total of 4453 patients were recorded in these studies.[14–20] Three[14,16,18] trials evaluated the effectiveness of immune checkpoint inhibitors for NSCLC patients having EGFR mutation or wild-type, including PD-1 (n = 915), PD-L1 (n = 713). Here, EGFR is linked to non-small cell lung carcinoma.